Pharmacological properties of oxotremorine and its analogs

Ringdahl, Björn; Jenden, Donald J.

doi:10.1016/0024-3205(83)90365-x

Cited by 66 publications

(17 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Wrst experiment was designed to clarify the role of the m1 receptor and its potential contribution to presynaptic inhibition in stratum radiatum of CA1 compared to previous work from this laboratory using the ACh agonist muscarine. Further, the M2-selective agonist oxotremorine (Puolivali, Jakala, Koivisto, & Riekkinen, 1998;Ringdahl & Jenden, 1983a, 1983b and purported M1-selective agonist MCN-A-343 (CaulWeld & Birdsall, 1998;Davies, Scholes, Virdi, & Broadley, 2001;Wess, 2003) were also administered to allow comparisons and incorporation of behavioral eVects in the neural models. However, the selectivity of…”

Section: Introductionmentioning

confidence: 99%

Muscarinic suppression in stratum radiatum of CA1 shows dependence on presynaptic M1 receptors and is not dependent on effects at GABAB receptors

Kremin

Gerber

Giocomo

et al. 2006

Neurobiology of Learning and Memory

View full text Add to dashboard Cite

Cholinergic modulation of synaptic transmission is vital to memory processes and may be responsible for setting network dynamics in the hippocampus appropriate for encoding of information. Sheridan and Sutor (1990) found evidence suggesting M1 receptors cause presynaptic inhibition of glutamatergic transmission, while Dutar and Nicoll (1988a) research supports a role of the M2 receptor. We examined muscarinic inhibition of fEPSPs in stratum radiatum of mice lacking m1 subtype receptors (KO) compared to wild type (WT) controls. WT mice exhibit greater suppression of transmission by muscarine as compared to KO in a dose dependent fashion. Oxotremorine shows no signiWcant diVerence in suppression between WT and KO, while MCN-A-343, an M1 agonist, exhibits a signiWcant diVerence between KO and WT, with KO showing no suppression. One hundred micromolar SGS-742, a selective GABA B antagonist, fails to aVect either normal transmission or muscarinic suppression in either WT or KO suggesting that diVerences in suppression between the groups is not attributable to diVerences in GABA B receptor activation due to muscarinic activation of GABAergic interneurons. These Wndings support a role for presynaptic m1 mAChRs in modulation of synaptic transmission in CA1, but indicate that other muscarinic receptor subtypes, such as M2, are also involved in suppression of synaptic potentials. 

show abstract

Section: Introductionmentioning

confidence: 99%

Muscarinic suppression in stratum radiatum of CA1 shows dependence on presynaptic M1 receptors and is not dependent on effects at GABAB receptors

Kremin

Gerber

Giocomo

et al. 2006

Neurobiology of Learning and Memory

View full text Add to dashboard Cite

show abstract

“…The effects of OXO can be blocked by administration of atropine, but not by hexamethonium (C 6 ). OXO has no effects on cholinesterase or on choline acetyltransferase activity at relevant concentrations [9]. Thus, the increased salivation and tremor responses to OXO in a5 À / À mice appear not to occur at the parasympathetic muscarinic receptor level, but rather on their central effects and interaction between parasympathetic and sympathetic nervous systems through centrifugal pathways.…”

Section: Discussionmentioning

confidence: 97%

Nicotinic acetylcholine receptor α5 subunits modulate oxotremorine-induced salivation and tremor

Wang

Orr-Urtreger

Chapman

et al. 2004

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…The non-selective muscarinic receptor agonist, oxotremorine [9], was employed as the challenge agent in the murine and rat models. Relatively selective antagonists at the M 2 and M 3 receptors, methoctramine [10,11] and 4-DAMP [12,13], respectively, were used for comparison.…”

Section: Discussionmentioning

confidence: 99%

In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine

et al. 2005

View full text Add to dashboard Cite

Background: Muscarinic receptor mediated adverse effects, such as sedation and xerostomia, significantly hinder the therapeutic usefulness of first generation antihistamines. Therefore, second and third generation antihistamines which effectively antagonize the H 1 receptor without significant affinity for muscarinic receptors have been developed. However, both in vitro and in vivo experimentation indicates that the third generation antihistamine, desloratadine, antagonizes muscarinic receptors. To fully examine the in vivo antimuscarinic efficacy of desloratadine, two murine and two rat models were utilized. The murine models sought to determine the efficacy of desloratadine to antagonize muscarinic agonist induced salivation, lacrimation, and tremor. Desloratadine's effect on the cardiovascular system was explored in both rodent models.

show abstract

Pharmacological properties of oxotremorine and its analogs

Cited by 66 publications

References 45 publications

Muscarinic suppression in stratum radiatum of CA1 shows dependence on presynaptic M1 receptors and is not dependent on effects at GABAB receptors

Muscarinic suppression in stratum radiatum of CA1 shows dependence on presynaptic M1 receptors and is not dependent on effects at GABAB receptors

Nicotinic acetylcholine receptor α5 subunits modulate oxotremorine-induced salivation and tremor

In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine

Contact Info

Product

Resources

About